dual anti-HER2/anti-IL-13Ra2 CAR T-cell therapy (Baylor College of Medicine)

N/A

Report date: 2025/03/19 09:00:06

Base Information

Drug Namedual anti-HER2/anti-IL-13Ra2 CAR T-cell therapy (Baylor College of Medicine)
Drug Alias Namedual anti-IL-13R alpha 2/anti-HER2 CAR T-cell therapy (Baylor College of Medicine)TanCAR T cell therapy (Baylor College of Medicine)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionInterleukin-13 receptor subunit alpha-2 modulatorsReceptor protein-tyrosine kinase erbB-2 modulators
TargetsReceptor protein-tyrosine kinase erbB-2Interleukin-13 receptor subunit alpha-2
Therapy Area/IndicationsGlioblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBaylor College Of Medicine
China Registration ClassN/A

Develop Information

Active CompaniesBaylor College Of Medicine
Inactive CompaniesN/A
Active IndicationsGlioblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A